key: cord-0822840-m3pk1189
authors: Hsu, Alan C-Y.; Wang, Guoqiang; Reid, Andrew T.; Veerati, Punnam Chander; Pathinayake, Prabuddha S.; Daly, Katie; Mayall, Jemma R.; Hansbro, Philip M.; Horvat, Jay C.; Wang, Fang; Wark, Peter A.
title: SARS-CoV-2 Spike protein promotes hyper-inflammatory response that can be ameliorated by Spike-antagonistic peptide and FDA-approved ER stress and MAP kinase inhibitors in vitro
date: 2020-10-01
journal: bioRxiv
DOI: 10.1101/2020.09.30.317818
sha: ca5245364c2790950226a990a84196197a40e507
doc_id: 822840
cord_uid: m3pk1189

SARS-CoV-2 infection causes an inflammatory cytokine storm and acute lung injury. Currently there are no effective antiviral and/or anti-inflammatory therapies. Here we demonstrate that 2019 SARS-CoV-2 spike protein subunit 1 (CoV2-S1) induces high levels of NF-κB activations, production of pro-inflammatory cytokines and mild epithelial damage, in human bronchial epithelial cells. CoV2-S1-induced NF-κB activation requires S1 interaction with human ACE2 receptor and early activation of endoplasmic reticulum (ER) stress, and associated unfolded protein response (UPR), and MAP kinase signalling pathways. We developed an antagonistic peptide that inhibits S1-ACE2 interaction and CoV2-S1-induced productions of pro-inflammatory cytokines. The existing FDA-approved ER stress inhibitor, 4-phenylburic acid (4-PBA), and MAP kinase inhibitors, trametinib and ulixertinib, ameliorated CoV2-S1-induced inflammation and epithelial damage. These novel data highlight the potentials of peptide-based antivirals for novel ACE2-utilising CoVs, while repurposing existing drugs may be used as treatments to dampen elevated inflammation and lung injury mediated by SARS-CoV-2.

The emergence of a novel SARS-coronavirus in late 2019 (SARS-CoV-2; previously known 53 as 2019-nCoV), and the CoV disease (COVID)-19 it causes, has led to a devastating 54 pandemic of the 21 st century. SARS-CoV-2 belongs to the beta-coronavirus genus with 55 approximately 79.5% sequence homology to the SARS-CoV that emerged in 2002 (Wang et 56 al., 2020b) . Similar to SARS-CoV (2002) , this novel CoV also utilises angiotensin converting 57 enzyme (ACE)2 as its host receptor to mediate membrane fusion and virus entry and viral 58 replication (Zhou et al., 2020) . SARS-CoV-2 spike protein contains two subunits, subunit 1 59 (S1) and S2, that mediates viral attachment to ACE2 and membrane fusion, respectively. The 60 receptor-binding domain (RBD) of S1 is the critical region of the spike protein for ACE2 61 binding. Currently there are no specific antiviral drugs available or anti-inflammatory drugs that have 80 been shown to influence clinical outcomes for people with COVID-19. A broad-spectrum 81 antiviral drug remdesivir is currently being used for COVID-19 through compassionate use 82 requests as well as in clinical trials in the US and China. The anti-malarial drug 83 hydroxychloroquine is also under several clinical trials, although preliminary reports have not 84 shown beneficial effects (Magagnoli et al., 2020; Mahevas et al., 2020) . 85 6 using streptavidin diminished interactions between CoV2-S1 and ACE2 in AP-6 group and 147 not in the non-AP-6-treated group. AP-6 also reduced CoV-S1 and ACE2 interaction, 148

indicating the inhibition potentials of AP-6 across small differences in amino acid residue 149 sequences between CoV2-S1 and CoV-S1 RBM (Figure S1B -C). 150 151 This indicates that CoV2-S1 elicits higher inflammatory responses than CoV-S1, and that the 152 CoV2-RBD alone is sufficient for inducing this response. CoV2-S1-ACE2 interaction is 153 required for this heightened inflammatory response. 154 155 CoV2-S1-ACE2 facilitates NF-κB activation via MAP kinase signalling. 156

We investigated if S1-mediated production of pro-inflammatory cytokines requires common 157 adaptor proteins MyD88 or TRIF. Knockdown of MyD88 or TRIF inhibited S1-mediated p65 158 phosphorylation ( Figure 3A) , indicating MyD88 and TRIF as important signalling adaptors in 159 S1-driven p65 activation. However, immunoprecipitation using anti-His antibody did not pull 160 down MyD88 or TRIF ( Figure 3B) with the PCR array. Here CoV2-S1 stimulation in BCi-NS1.1 cells also induced heightened 174 activation of MAP kinase p38 (12 -24hrs), Erk (2 and 24hrs), and Jnk (24hrs), compared to 175 inductions by CoV-S1 ( Figure 4A ). Knockdown of p38, Erk or Jnk expressions by siRNAs 176 all resulted in a significant reduction in phosphorylation of p65 following CoV2-S1 treatment 177 ( Figure 4B ), indicating that the MAP kinase is an important contributor to CoV2-S1-178 mediated NF-κB activation. 179 7 CoV2-S1 stimulates rapid ER stress and UPR that activate NF-κB via UPR-MAP kinase 181

CoV2-S1 induced early activation of Erk, which is a kinase utilised by not only MAP kinase 183 but also ER stress and UPR. ER stress has been shown to be induced by the CoV spike 184 protein (Versteeg et al., 2007) . ER-UPR features three main pathways, PERK-Erk-CHOP 185 pathway that modulates apoptosis, ATF6 that regulates protein folding, and the IRE1 -186 TRAF2 pathway that promotes NF-κB and p38 activation (Pathinayake et al., 2018) . 187

CoV2-S1 and -RBD resulted in an early increase of IRE1 and PERK activations at 2 and 188 6hrs, respectively, and this was sustained to 24hr post stimulation. Furthermore, IRE1 and 189 PERK activations were higher compared with CoV-S1 and -RBD ( Figure 5A ). ATF6 190 activation was equivalent for CoV2-S1 and CoV-S1. As IRE1 activation was induced 191 earlier (2hrs) by CoV2-S1 than MAP kinases, we then investigated if increased ER-UPR by 192

CoV2-S1 leads to heightened MAP kinase activities by siRNAs. 193

Knockdown of PERK resulted in reduced phosphorylation levels of Erk, but had minimal 195 effect on p65, p38, and Jnk activation ( Figure 5B ). In contrast, reduction of IRE1 196 expression decreased p65, p38, and Erk phosphorylation/expression. This indicates that 197 IRE1 , and not PERK and ATF6 pathway, is involved in p65 activation. 198

We also assessed if MAP kinase modulates ER-UPR. While knockdown of either p38, Erk, 199 or Jnk decreased p65 phosphorylation ( Figure 4B ), reduction of p38 or Erk gene expression 200 led to decreased PERK phosphorylation but not IRE1 activation ( Figure 5C ). Jnk 201 knockdown led to reduced IRE1 phosphorylation and had no effect on PERK activation. 202

This demonstrates CoV2-S1 promotes NF-κB activation via the ER-UPR (IRE1 /PERK) and 203 MAP kinase pathway. 204 205

Acute lung injury is a feature observed with severe COVID-19 (Huang et al., 2020; Lai et al., 207 2017) , and markers associated with epithelial damage IL-1β, TNF , and CCL2 were all 208 markedly increased by CoV2-S1 in our targeted PCR array ( Figure 3C ), and at protein levels 209 ( Figure 1A ). CoV2-S1 also significantly up-regulated protein productions of CCL2 in BCi-210 NS 1.1 cells ( Figure 6A ). To further investigate if CoV2-S1 induces epithelial damage, we 211 stimulated differentiated primary bronchial epithelial cells (pBECs) cultured at air-liquid 212 interface (ALI) with CoV2-S1 (50 and 100ng). Stimulation resulted in a significant reduction 213 8 in transepithelial electrical resistance (TEER; Figure 6B ), demonstrating an increased 214 epithelial permeability and tight junction disruption caused by CoV2-S1. This is 215 accompanied with increased protein production of epithelial damage factors IL-1β, TNF , 216 and CCL2, in a CoV2-S1 dose-dependent manner ( Figure 6C -E). 217 Immunofluorescent staining of a tight junction protein zonula occludens-1 (ZO-1) showed 218 strong localisation at the cell borders in the non-stimulated controls, whereas CoV2-S1 led to 219 partial disappearance of ZO-1 at the cell borders ( Figure 6F ). This indicates that CoV2-S1 220 may also disrupt epithelial barrier function. 221 222 CoV2-S1-antagonistic AP-6 and FDA-approved ER stress and MAP kinase inhibitors 223 ameliorate CoV2-mediated inflammatory response. 224

CoV2-S1 induced NF-κB activation and subsequent production of pro-inflammatory 225 cytokines was dependent on ACE2 interaction and early ER-UPR and MAP kinase activities. 226

We therefore assessed whether CoV2-S1-mediated inflammation could be reduced by our 227

CoV2-S1 inhibitory peptide AP-6, or with existing FDA-approved pharmacological 228 inhibitors, that target ER stress (4-PBA) or MAP kinase (trametinib and ulixertinib). 229 230 Treatment with AP-6 led to a significant decrease in CoV2-S1-mediated phosphorylation of 231 p65 ( Figure 2C ) and production of IL-6, IL-1β, TNF , but not CCL2 ( Figure 7A -D) in a 232 dose-dependent manner. Similarly, the ER stress inhibitor 4-PBA and both MAP kinase 233 inhibitors led to decreased activation of p65 ( Figure S3 ) and expression of these pro-234 inflammatory and epithelial injury cytokines ( Figure 7E -L). These drugs had no effect on 235 non-CoV2-S1-stimulated controls ( Figure S4 ). CoV2-S1-induced reduction in barrier 236 integrity and ZO-1 was prevented via treatment with AP-6 and FDA-approved inhibitors, 237 suggesting maintained barrier function ( Figure S5A -B). This strongly indicates that AP-6 238 could serve as a proof-of-concept therapeutic peptides against SARS-CoV-2 and also that ER 239 stress / MAP kinase inhibitors could be used to reduce inflammation and lung injury caused 240 by CoV2-S1. 241 242 Discussion 243

CoV Spike protein and host ACE2 interaction is a critical first step to viral replication and 244

diseases. Here we demonstrate that CoV2 S1 subunit and RBD induces early ER-UPR and 245 MAP kinase activations, leading to hyper-inflammatory responses. Our results indicate that 9 this inflammatory storm, and downstream consequences are inhibited by S1-inhibitory 247 peptides and existing FDA-approved ER stress and MAP kinase inhibitors ( . SARS-CoV-2 S1 and RBD alone induced heightened levels of IL-252 6, TNF and IL-1β, and the productions of which were higher compared with CoV-S1. This 253 induction occurs in an ACE2-dependent manner, and the higher affinity of CoV2-S1 towards 254 ACE2 may have contributed to this elevated inflammatory response (Wang et al., 2020a) . 255

CoV2-S1-mediated NF-κB activation is also dependent on common TLR adaptor proteins 256

MyD88 and TRIF, although we could not detect interactions between ACE2 and these 257 adaptor proteins. It is possible that CoV2-S1-ACE2 interaction triggers MyD88 and TRIF 258 activations via other signalling factors that then result in NF-κB activation. 259

Our data strong indicates that inflammation could be triggered by CoV2-S1 even before viral 261 replication occurs or in the absence of viral replication. As CoV2-S1 is present throughout 262 viral replication cycles and infection, our data demonstrate that spike proteins are likely to be 263 a major contributor to inflammation. The constant presence of S1 is consistent with the high 264 viral load and a long virus-shedding period observed in patients with severe COVID-19 (Liu 265 et al., 2020). Furthermore, CoV2 spike protein has an estimated half-life of 30 hours in 266 mammalian systems (in silico analysis by ExPASy ProtParam) and consists of amino acid 267 residues with long half-lives (leucine (8%), threonine (7.6%), valine (7.6%), alanine (6.2%), 268 glycine (6.4%), and proline (4.6%)). This may suggest persistent presence of CoV2 spike 269 protein from live and dead viruses that plays major role in triggering the inflammatory storm 270 in COVID-19. Importantly, our antagonistic peptide inhibited this binding event and reduced 271 the production of pro-inflammatory cytokines. While peptide sequence optimisations are 272 required to further increase effectiveness and stability, this highlights the potentials of using 273 S1 antagonistic peptides as neutralising molecules against SARS-CoV-2. that halts protein translation ; ATF6 that facilitates protein folding as 281 well as NF-κB activation (Shen et al., 2005) ; and IRE1 promotes NF-κB phosphorylation 282 and inflammation (Urano et al., 2000) . Here we showed that both ER-UPR and MAP kinases 283 modulate CoV2-S1-induced NF-κB activations. 284 285 CoV2-S1 caused early activation of ER-UPR IRE1 and PERK-Erk, leading to MAP kinases 286 phosphorylations, which then facilitated NF-κB-mediated production of pro-inflammatory 287 cytokines. Although IRE1 activation occurred earlier than other ER-UPR and MAP kinase 288 factors, it is likely that CoV2-S1 can promote NF-κB activation via ER-UPR and MAP comparison of IL-6, IL-1β and TNF by CoV2-S1 and CoV-S1. G. Immunoblot (left) and 356 densitometry (right) of induction kinetics of phospho(p)-p65 at 2, 6, 12, and 24hr post 357 stimulation by CoV2-S1 and CoV-S1 compared with CoV2-S1 stimulated but untreated CoV2-S1/-RBD or CoV-2-S1/-RBD stimulation. B. Schematic representation of CoV2-S1 366 protein and peptide design coverage. C. Immunoblot of p-p65 and p65 24hrs post CoV2-S1 367 stimulation and CoV2-S1 antagonistic peptides (AP-1 -6) compared with untreated control 368 (U). D. Immunoblot (left) and densitometry (right) of p-p65 and p65 at 24hrs post CoV2-S1 369 and AP-6 (10, 25µM) treatment compared with CoV2-S1 stimulated but untreated control 370 (U). E. Immunoblot of ACE2 and His following immunoprecipitation using anti-His antibody 371 30 minutes post CoV2-S1/AP-6 treatment. Immunoblot of His and ACE2 following 372 Erk, p-Jnk and Jnk at 2, 6, 12, and 24hr post stimulation by CoV2-S1 and CoV-S1 compared 390 with untreated control (U). B. Immunoblots of p-p65, p65, p-p38, p38, p-Erk, Erk, p-Jnk and 391

Jnk 24hrs post CoV2-S1 or -RBD stimulation in p38, Erk or Jnk silenced BCi-NS1.1. N = 3. 392

Immunoblots shown are representative of three independent experiments and β -actin was 393 detected to show equal protein input (lower panel). * P ≤ 0.05 versus untreated control. 394 395 Figure 5 . CoV2-S1 induces rapid ER-UPR that activate NF-κB via ER-MAP kinase 396

A. Immunoblot (top) and densitometry (bottom) of induction kinetics of p-IRE1 , IRE1 , p-398 ATF6, ATF6, p-PERK and PERK at 2, 6, 12, and 24hr post stimulation by CoV2-S1 and 399

CoV-S1 compared with untreated control (U). B. Immunoblots of p-p65, p65, p-p38, p38, p-400 Erk, Erk, p-Jnk, Jnk, IRE1 and PERK 24hrs post CoV2-S1 or -RBD stimulation in PERK 401 and IRE1 silenced BCi-NS1.1. C. Immunoblots of p-PERK and p-IRE1 post CoV2-S1 or 402 were air-lifted by removing apical media and changing basal media into ALI final media (as 465 described above for ALI initial media but with 0.5ng/mL of rhEGF). Transepithelial 466 resistance (TEER) was measured every seven days using a EVOM2 Epithelial Voltohmmeter 467 (World Precision Instruments, USA). The basal media was replaced with fresh ALI final 468 media every second day. pBECs were cultured at ALI for 25 days and then used for 469 experiments. All cells were cultured and maintained at 37°C / 5% CO 2 . 470 471

Spike protein subunit 1 (S1) and receptor binding domain (RBD) stimulation 473

For cells cultured in submerged and at ALI conditions, his-tagged S1 and RBD (Sino 474 Biological Inc.) was diluted in BEBM minimal media (Lonza, Switzerland) and added to the 475 cells. For pBECs at ALI, S1 and RBD was added to the apical side. 476 477 CoV2-S1 antagonistic peptides 1 1 7

Immunoblotting and immunoprecipitation 514 S1-stimulated cells were lysed in protease-inhibitor cocktail supplemented RIPA buffer 515 (Roche, UK). Proteins were subjected to SDS-PAGE (Bio-Rad Laboratories, USA) and 516 transferred onto polyvinylidene fluoride membranes (Merck-Milipore, USA). Proteins were 517 detected using antibodies to His, MyD88, TRIF, p65, phospho-(p)-p65, p38, p-p38, Erk, p-518

Erk, Jnk, p-Jnk, PERK, p-PERK, IRE1 , and p-IRE1 antibodies (All from Abcam, UK). 519

Antibody to ACE2 was obtained from RnD Systems (USA). For immunoprecipitation, whole 520 cell lysates (1mg) were immunoprecipitated using anti-His antibody or isotytpe antibody 521 Data were analysed on GraphPad Prism 8. Statistical significance of differences was assessed 544 using parametric Student's two tailed t test for normally distributed data and Mann-Whitney 545 U test for non-parametric data. Differences were considered significant when p< 0.05. 1 8 547 Figure S1 . AP-6 reduces CoV-S1 and ACE2 interaction. 548

A. Cell viability measured by annexin-V/7-AAD staining and flow cytometry. B. 549

Immunoblot of ACE2 and His following immunoprecipitation using anti-His antibody 30 550 minutes post CoV2-S1/AP-6 treatment. N = 3. Immunoblots shown are representative of 551 three independent experiments. C. Amino acid residue sequence alignments of CoV2-S1 and 552

CoV-S1. Blue = AP-6 contact region. Sequence alignment performed by Clustal Omega. 553 554 Figure S2 . CoV2-S1 up-regulates genes involved in inflammation, inflammasome and 555

CoV2-S1-stimulated BCi-NS1.1 cells were subjected to RT 2 Profiler TM Human 557

Inflammasone PCR array with highly up-regulated genes involved in NF-κB, Inflammasome, 558 and MAP kinase pathways. N=3. 559 560 Figure S3 . CoV2-S1 antagonistic peptides, Trametinib, and Ulixertinib had no effect on 561 IL-6, IL-1β, TNF , and CCL2 productions in non-CoV2-S1-treated cells. CoV2-S1 stimulation and treatment with either AP-6, 4-PBA, trametinib, and ulixertinib. N = 576 3. * P ≤ 0.05 versus non-CoV2-S1-stimulated control, + versus CoV2-S1-stimulated group. B. 577

Immunofluorescent images of ZO-1 staining. N = 2. 578 579 1 9

Mechanism of IL-1beta modulation of intestinal epithelial barrier involves p38 kinase and 583 activating transcription factor-2 activation

Recognition of double-stranded 585 RNA and activation of NF-kappaB by Toll-like receptor 3

IkappaBalpha degradation 587 and nuclear factor-kappaB DNA binding are insufficient for interleukin-1beta and tumor necrosis 588 factor-alpha-induced kappaB-dependent transcription. Requirement for an additional activation 589 pathway

Oral sodium phenylbutyrate therapy in homozygous beta thalassemia: a clinical trial

Innate antiviral 593 responses by means of TLR7-mediated recognition of single-stranded RNA

Ginsenoside Rg3 ameliorates acute exacerbation of COPD by suppressing 596 neutrophil migration

Perk is essential for 598 translational regulation and cell survival during the unfolded protein response

RIPLET, and not TRIM25, is required for 602 endogenous RIG-I-dependent antiviral responses

Trametinib: A Targeted Therapy in Metastatic Melanoma

Human influenza is more effective than 606 avian influenza at antiviral suppression in airway cells

MicroRNA-125a and -b inhibit A20 and MAVS to promote 610 inflammation and impair antiviral response in COPD

Critical role of constitutive type I interferon response in bronchial epithelial cell to influenza 613 infection

Impaired Antiviral Stress Granule and IFN-beta Enhanceosome Formation Enhances

Susceptibility to Influenza Infection in Chronic Obstructive Pulmonary Disease Epithelium. American 617 journal of respiratory cell and molecular biology

Targeting PI3K-p110alpha Suppresses Influenza Virus

Infection in Chronic Obstructive Pulmonary Disease. American journal of respiratory and critical care 621 medicine 191

Respiratory syncytial virus co-opts host mitochondrial 624 function to favour infectious virus production

Clinical features of patients infected with 2019 novel coronavirus in

Progesterone and calcitriol attenuate 629 inflammatory cytokines CXCL1 and CXCL2 in ovarian and endometrial cancer cells

Suppressor of cytokine signaling (SOCS)5 ameliorates 633 influenza infection via inhibition of EGFR signaling

Protection of 635 human corneal epithelial cells from TNF-alpha-induced disruption of barrier function by rebamipide

Interleukin-1beta-induced disruption of barrier 638 function in cultured human corneal epithelial cells

Transient expression of 640

IL-1beta induces acute lung injury and chronic repair leading to pulmonary fibrosis

Chemokine Ligand 2 (CCL2) Mediates Acute Lung Injury Induced by Lethal Influenza H7N9 Virus. 644 Frontiers in microbiology

Cutting Edge: Influenza A virus activates TLR3-dependent inflammatory and RIG-I-dependent 647 antiviral responses in human lung epithelial cells

Altered p38 mitogen-activated protein kinase expression in different leukocytes with 650 increment of immunosuppressive mediators in patients with severe acute respiratory syndrome

Structure of SARS coronavirus spike receptor-653 binding domain complexed with receptor

Ammonia control in children 656 with urea cycle disorders (UCDs); phase 2 comparison of sodium phenylbutyrate and glycerol 657 phenylbutyrate

Fibulin-1c regulates transforming growth factor-beta 660 activation in pulmonary tissue fibrosis

Fibulin-1 regulates the pathogenesis of tissue remodeling in 663 respiratory diseases

Airway remodelling and inflammation in asthma are dependent on 666 the extracellular matrix protein fibulin-1c

Viral dynamics in mild and severe cases of COVID-19

Akt stimulates the 670 transactivation potential of the RelA/p65 Subunit of NF-kappa B through utilization of the Ikappa B 671 kinase and activation of the mitogen-activated protein kinase p38

Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19. 675 medRxiv

No evidence of clinical efficacy of hydroxychloroquine in 678 patients hospitalized for COVID-19 infection with oxygen requirement: results of a study using 679 routinely collected data to emulate a target trial. medRxiv

The Role of Cytokines 681 including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-682

COVID-19: consider cytokine storm syndromes and 685 immunosuppression

Protective effects of 4-phenylbutyrate derivatives on the neuronal cell death and 688 endoplasmic reticulum stress

Phosphorylation of p38 690 MAPK and its downstream targets in SARS coronavirus-infected cells

Measuring ER stress and the unfolded protein response using 693 mammalian tissue culture system

Chemical chaperones reduce ER stress and restore glucose homeostasis in 696 a mouse model of type 2 diabetes

TLR3 and MDA5 signalling, although not 698 expression, is impaired in asthmatic epithelial cells in response to rhinovirus infection

Understanding the Unfolded Protein Response in the Pathogenesis of

Blocking Notch3 Signaling Abolishes

MUC5AC Production in Airway Epithelial Cells from Individuals with Asthma. American journal of 705 respiratory cell and molecular biology

Differential recognition of double-stranded RNA by RIG-I-like 707 receptors in antiviral immunity

Stable binding of ATF6 to BiP 709 in the endoplasmic reticulum stress response

Pentoxifylline treatment 711 attenuates pulmonary vasomotor dysfunction in acute lung injury

First-in-Class ERK1/2 Inhibitor Ulixertinib

in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and 715 Expansion Study

Coupling of stress in the ER to activation of JNK protein kinases by transmembrane protein kinase 718 IRE1

Nasal epithelial cells 720 to assess in vitro immune responses to respiratory virus infection in pregnant women with asthma

The coronavirus spike 723 protein induces endoplasmic reticulum stress and upregulation of intracellular chemokine mRNA 724 concentrations

Generation of a human airway epithelium derived basal 727 cell line with multipotent differentiation capacity

Combined treatment with SB203580 and dexamethasone suppresses

typeable Haemophilus influenzae-induced Th17 inflammation response in murine allergic asthma

Toll-like receptor-mediated activation of neutrophils by influenza A virus

Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2

-2 infects T lymphocytes through its spike protein-mediated membrane fusion

Activation of 741 transcription factor NF-kappaB and p38 mitogen-activated protein kinase is mediated by distinct and 742 separate stress effector pathways

A pneumonia outbreak associated with a new coronavirus of probable bat origin

RNAs from S1-stimulated cells were extracted using RNeasy Mini Kits and QIAcube 506 (Qiagen, USA) according to manufacturer's instruction. 200ng of RNAs were reverse 507 transcribed to cDNA using random primers (Applied Biosystem, USA). cDNAs were then 508 subjected to pathway-focused gene expression array using RT 2 Profiler TM Human 509Inflammasome PCR array (Qiagen, USA). The raw data was analysed by the Data Analysis 510Center on Qiagen website (https://www.qiagen.com/mx/shop/genes-and-pathways/data-511 analysis-center-overview-page/).